137 related articles for article (PubMed ID: 21153394)
1. [Plasma E-cadherin levels in urinary bladder cancer: does it improve risk stratification?].
Szarvas T; Hoffmann F; Becker M; Schenck M; Vom Dorp F; Rübben H; Jäger T
Urologe A; 2011 Jan; 50(1):64-70. PubMed ID: 21153394
[TBL] [Abstract][Full Text] [Related]
2. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy.
Matsumoto K; Shariat SF; Casella R; Wheeler TM; Slawin KM; Lerner SP
J Urol; 2003 Dec; 170(6 Pt 1):2248-52. PubMed ID: 14634390
[TBL] [Abstract][Full Text] [Related]
3. Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence.
Griffiths TR; Brotherick I; Bishop RI; White MD; McKenna DM; Horne CH; Shenton BK; Neal DE; Mellon JK
Br J Cancer; 1996 Aug; 74(4):579-84. PubMed ID: 8761373
[TBL] [Abstract][Full Text] [Related]
4. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.
Byrne RR; Shariat SF; Brown R; Kattan MW; Morton RA JR; Wheeler TM; Lerner SP
J Urol; 2001 May; 165(5):1473-9. PubMed ID: 11342899
[TBL] [Abstract][Full Text] [Related]
5. The impact of transurethral resection of bladder tumour on serum levels of soluble E-cadherin.
Durkan GC; Brotherick I; Mellon JK
BJU Int; 1999 Mar; 83(4):424-8. PubMed ID: 10210565
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy.
Kashibuchi K; Tomita K; Schalken JA; Kume H; Takeuchi T; Kitamura T
Int J Urol; 2007 Sep; 14(9):789-94. PubMed ID: 17760743
[TBL] [Abstract][Full Text] [Related]
7. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma.
Chan AO; Lam SK; Chu KM; Lam CM; Kwok E; Leung SY; Yuen ST; Law SY; Hui WM; Lai KC; Wong CY; Hu HC; Lai CL; Wong J
Gut; 2001 Jun; 48(6):808-11. PubMed ID: 11358900
[TBL] [Abstract][Full Text] [Related]
8. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Shariat SF; Monoski MA; Andrews B; Wheeler TM; Lerner SP; Slawin KM
Urology; 2003 May; 61(5):1053-8. PubMed ID: 12736046
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer.
Zhao J; Dong D; Sun L; Zhang G; Sun L
Int Braz J Urol; 2014; 40(2):179-89. PubMed ID: 24856504
[TBL] [Abstract][Full Text] [Related]
10. Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer.
Szarvas T; Jäger T; Becker M; Tschirdewahn S; Niedworok C; Kovalszky I; Rübben H; Ergün S; vom Dorp F
Pathol Oncol Res; 2011 Jun; 17(2):325-32. PubMed ID: 21253919
[TBL] [Abstract][Full Text] [Related]
11. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
Mahnken A; Kausch I; Feller AC; Krüger S
Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy.
Kawahara T; Furuya K; Nakamura M; Sakamaki K; Osaka K; Ito H; Ito Y; Izumi K; Ohtake S; Miyoshi Y; Makiyama K; Nakaigawa N; Yamanaka T; Miyamoto H; Yao M; Uemura H
BMC Cancer; 2016 Mar; 16():185. PubMed ID: 26944862
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of cadherin switch in bladder cancer.
Jäger T; Becker M; Eisenhardt A; Tilki D; Tötsch M; Schmid KW; Romics I; Rübben H; Ergün S; Szarvas T
Oncol Rep; 2010 Apr; 23(4):1125-32. PubMed ID: 20204300
[TBL] [Abstract][Full Text] [Related]
14. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer.
Cantiello F; Russo GI; Vartolomei MD; Farhan ARA; Terracciano D; Musi G; Lucarelli G; Di Stasi SM; Hurle R; Serretta V; Busetto GM; Scafuro C; Perdonà S; Borghesi M; Schiavina R; Cioffi A; De Berardinis E; Almeida GL; Bove P; Lima E; Ucciero G; Matei DV; Crisan N; Verze P; Battaglia M; Guazzoni G; Autorino R; Morgia G; Damiano R; de Cobelli O; Mirone V; Shariat SF; Ferro M
Eur Urol Oncol; 2018 Oct; 1(5):403-410. PubMed ID: 31158079
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.
Breyer J; Gierth M; Shalekenov S; Aziz A; Schäfer J; Burger M; Denzinger S; Hofstädter F; Giedl C; Otto W
World J Urol; 2016 May; 34(5):709-16. PubMed ID: 26394624
[TBL] [Abstract][Full Text] [Related]
16. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
17. Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer.
Protheroe AS; Banks RE; Mzimba M; Porter WH; Southgate J; Singh PN; Bosomworth M; Harnden P; Smith PH; Whelan P; Selby PJ
Br J Cancer; 1999 Apr; 80(1-2):273-8. PubMed ID: 10390008
[TBL] [Abstract][Full Text] [Related]
18. Dual role of serum soluble E-cadherin as a biological marker of metastatic development in gastric cancer.
Juhasz M; Ebert MP; Schulz HU; Röcken C; Molnar B; Tulassay Z; Malfertheiner P
Scand J Gastroenterol; 2003 Aug; 38(8):850-5. PubMed ID: 12940439
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.
Lin YL; Sun G; Liu XQ; Li WP; Ma JG
J Int Med Res; 2011; 39(1):179-86. PubMed ID: 21672320
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-To-Mesenchymal Transition and Its Correlation With Clinicopathologic Features in Patients With Urothelial Carcinoma of the Bladder.
Singh R; Ansari JA; Maurya N; Mandhani A; Agrawal V; Garg M
Clin Genitourin Cancer; 2017 Apr; 15(2):e187-e197. PubMed ID: 27601277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
